Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for Leukoplakia
NCT03603223Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- May 2019
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in leukoplakia and erythroleukoplakia, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Clinical response rate at 6 months. Started May 2019; status: recruiting.
02
Drugs
03
Conditions
leukoplakiaerythroleukoplakia
Beyond the preview
Go deeper on NCT03603223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603223.